<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02299297</url>
  </required_header>
  <id_info>
    <org_study_id>AAAO1502</org_study_id>
    <nct_id>NCT02299297</nct_id>
  </id_info>
  <brief_title>Study To Evaluate The Efficacy Of Tofacitinib In Moderate To Severe Alopecia Areata, Totalis And Universalis</brief_title>
  <official_title>An Open-Label Pilot Study To Evaluate The Efficacy Of Tofacitinib In Moderate To Severe Alopecia Areata, Totalis And Universalis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Columbia University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Locks of Love</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Columbia University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is an open-label pilot study of tofacitinib taken daily for 6 months in the treatment of
      moderate to severe AA, and alopecia totalis or universalis, followed by 6 months follow-up
      off drug to assess the incidence and timing of recurrence of disease or documentation of
      delayed response to treatment. There will be the option of increasing the treatment duration
      up to an additional 6 months beyond the initially scheduled 6 months of treatment, if
      clinically indicated, and at the discretion of the investigator.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Alopecia areata (AA) is a common disease of the immune system, known as an &quot;autoimmune&quot;
      disease. In the disease, the immune system mistakenly destroys the hair follicle, causing
      hair to fall out. Despite many people having this disease, research into its cause and new,
      better ways to treat AA has lagged far behind other similar diseases of the immune system.
      Currently, there are no Federal Drug Administration approved drugs for AA.

      Tofacitinib (made by Pfizer) is an intervention known to effectively treat a disease of the
      joints, known as rheumatoid arthritis. It is also being studied in the treatment of
      psoriasis, another &quot;autoimmune&quot; disease, by fighting inflammation. There are some genetic and
      chemical similarities between those with active rheumatoid arthritis, psoriasis, and
      AA,suggesting that treatment with the same drug is likely to be effective. In mice specially
      designed for testing drugs for the treatment of human alopecia, this medication worked to
      prevent the disease AA from starting in mice that would have otherwise developed the disease.
      To test Tofacitinib, we are going to treat 15 patients with moderate to severe AA for up to 6
      months. This is an &quot;open label&quot; study, meaning that there will not be a placebo group; all
      patients enrolled in the study will receive the active medication. The effectiveness of the
      medication will be measured by changes in hair re-growth as determined by physical exam and
      photography, as well as by patient and physician scoring. After the treatment period of up to
      6 months is completed, There will be the option of increasing the treatment duration up to an
      additional 6 months beyond the initially scheduled 6 months of treatment, if clinically
      indicated, and at the discretion of the investigator. Patients will be followed for another 6
      months off of the drug to see if the effects of treatment last and if there is delayed
      response. The safety of the medication, Tofacitinib, in patients with AA will also be
      evaluated. Blood work will be collected before medication is started, during the treatment
      period and after Tofacitinib is stopped in order to monitor for adverse effects of the
      medication. Small scalp biopsies and peripheral blood will be taken at the beginning of the
      study before treatment and at weeks 4 and 24. Additional, optional scalp biopsies and blood
      draws may be suggested at other important time points. The chemical analysis of these skin
      samples and blood will help us to understand how the disease happens, how the treatment
      works, and even guide us to better treatments in the future.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">January 2015</start_date>
  <completion_date type="Actual">December 2017</completion_date>
  <primary_completion_date type="Actual">December 2017</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Total Number of Responders</measure>
    <time_frame>Baseline up to between 24 and 72 weeks</time_frame>
    <description>This is defined as 50% or greater hair re-growth from baseline as assessed by the Severity of ALopecia Tool (SALT) score after up to 24 weeks/6 months to 72 weeks/18 months of treatment. This is a relatively strict definition for defining responders and non-responders and was chosen to minimize the potential for spontaneous remission, in which fewer than 10% are expected to achieve this magnitude of hair regrowth spontaneously.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Total Number of Responders Maintaining Response During the Post-Treatment Follow Up Period</measure>
    <time_frame>Week 24</time_frame>
    <description>To assess the durability of responses, patients who achieve 50% regrowth from baseline during the first 6 to 18 months, will continue to be followed for an additional 6 months post-treatment or until it is determined that relapse has occurred. Durability of response was measured by comparing SALT scores from baseline to 24 weeks after treatment.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Total Number of Responders With Change in PHYSICIAN Global Assessment Score</measure>
    <time_frame>Up to 24 weeks</time_frame>
    <description>A physician's assessment of the severity of disease based on a 6-point scale (score of 0 = clear and 5 = very severe). Responders are defined by participants who exhibited regrowth.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Regrowth</measure>
    <time_frame>Baseline up to between 24 and 72 weeks</time_frame>
    <description>Percentage of regrowth was measured by comparing the SALT score at the beginning and end of treatment.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Dermatology Life Quality Index (DLQI) Score</measure>
    <time_frame>Up to 24 weeks</time_frame>
    <description>The first dermatology-specific Quality of Life instrument. It is a simple 10-question validated questionnaire used to evaluate patient's quality of life. The DLQI is calculated by summing the score of each question resulting in a maximum of 30 and a minimum of 0. The higher the score, the more quality of life is impaired.</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">12</enrollment>
  <condition>Alopecia Areata</condition>
  <arm_group>
    <arm_group_label>Tofacitinib</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Tofacitinib will be self-administered for 6 months, with the option to extend treatment up to an additional 6 months at the discretion of the principal investigator. Patients will then be followed for 6 months off the drug to assess the incidence and timing of recurrence of disease or documentation of delayed response to treatment.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Tofacitinib</intervention_name>
    <description>Dosage/Frequency: 5mg - 10mg, oral, twice daily</description>
    <arm_group_label>Tofacitinib</arm_group_label>
    <other_name>XELJANZ</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients between 18 and 65 years of age.

          -  Patients with a diagnosis of moderate to severe patch type alopecia areata.

          -  Patients with alopecia totalis or universalis may be enrolled.

          -  Patients have &gt;30% and &lt;95% total scalp hair loss at baseline as measured using the
             SALT score to qualify as moderate to severe patch type AA; and 95-100% scalp hair loss
             to qualify as alopecia totalis or universalis.

          -  Duration of hair loss greater than 3 months without an upper limit of duration as long
             as there is reason to believe that regrowth is possible in the opinion of the
             investigator.

          -  No evidence of significant active ongoing regrowth present at baseline.

          -  Patients with a history of alopecia totalis/universalis can be included as long as the
             current episode of hair loss meets the criteria of 30 to 95% hair loss (i.e. they are
             not currently AT or AU), and as long as in the opinion of the investigator there does
             appear to be potential for regrowth. Patients with current episodes of alopecia
             totalis/universalis may be included in this study.

          -  Vaccinations should be up to date in agreement with current immunization guidelines
             prior to start of tofacitinib. The patient will be asked to obtain verbal verification
             from their primary care provider that this is the case.

          -  Patients may be na√Øve to treatment or unresponsive to intralesional (IL) steroids or
             other treatments for alopecia areata.

          -  Women of childbearing potential (WOCBP) must use highly effective methods of birth
             control [for at least 12 weeks after the last dose of investigational product] to
             minimize the risk of pregnancy. WOCBP must follow instructions for birth control for
             the entire duration of the study including a minimum of 90 days after dosing has been
             completed.

        Acceptable methods of highly effective birth control include:

          -  Condom with spermicide

          -  Diaphragm and spermicide

          -  Cervical cap and spermicide The use of intrauterine devices, (IUDs) shall be at the
             discretion of the investigator.

               1. Women must have a negative serum or urine pregnancy test (minimum sensitivity 25
                  IU/L or equivalent units of HCG) within 24 hours prior to the start of
                  investigational product.

               2. Women must not be breastfeeding.

        Exclusion Criteria:

          -  Sex and Reproductive Status

               1. WOCBP who are unwilling or unable to use an acceptable method to avoid pregnancy
                  for the entire study period and for up to 12 weeks after the last dose of study
                  drug.

               2. WOCBP using a prohibited contraceptive method.

               3. Women who are pregnant or breastfeeding.

               4. Women with a positive pregnancy test on enrollment or before administration of
                  tofacitinib.

               5. Sexually active fertile men not using effective birth control if their partners
                  are WOCBP.

          -  Target Disease Exceptions

               1. Patients with current alopecia totalis/universalis (i.e. 100% scalp or 100% scalp
                  and body loss, respectively) may be enrolled.

               2. Patients with a history of or active skin disease on the scalp such as psoriasis
                  or seborrheic dermatitis.

               3. Patients in whom the diagnosis of alopecia areata is in question or in whom the
                  pattern of hair loss is such that quantification of hair loss and assessment of
                  regrowth is difficult. E.g patients with diffuse alopecia areata. This assessment
                  is at the investigator's discretion.

               4. Patients with active medical conditions or malignancies (except adequately
                  treated basal or squamous cell carcinoma) that in the opinion of the investigator
                  would increase the risks associated with study participation, including patients
                  with a history of recurrent infections.

               5. Patients with hemoglobin levels &lt;9 g/dL, lymphocyte count &lt;500 cells/mm3,
                  absolute neutrophil count (ANC) &lt;1000 cells/mm3, at baseline.

               6. Patients known to be HIV or hepatitis B or C positive.

               7. Patients with history or evidence of moderate or severe hepatic and/or renal
                  impairment.

               8. Patients with history of immunosuppression or history of recurrent serious
                  infections.

          -  Coexisting disease or concurrent medications

               1. Patients taking potent inhibitors of CYP3A4 (e.g.ketoconazole).

               2. Patients receiving one or more concomitant medications that result in both
                  moderate inhibition of CYP3A4 and potent inhibition of CYP2C19 (e.g.,
                  fluconazole).

               3. Patients known to be HIV or hepatitis B or C positive.

               4. Patients with evidence of infection or active/untreated skin cancer.

               5. Patients who have been treated with intralesional steroids, systemic steroids,
                  anthralin, squaric acid, diphenylcyclopropenone (DPCP), protopic, minoxidil or
                  other medication which in the opinion of the investigator may affect hair
                  regrowth within one month of the baseline visit.

               6. Patients who are impaired, incapacitated, or incapable of completing
                  study-related assessments.

               7. Patients with current symptoms of severe, progressive, or uncontrolled renal,
                  hepatic, hematologic, gastrointestinal, pulmonary, cardiac, neurologic, or
                  cerebral disease, which, in the opinion of the investigator, might place a
                  subject at unacceptable risk for participation in the study.

               8. Female patients who have had a breast cancer screening that is suspicious for
                  malignancy and in whom the possibility of malignancy cannot be reasonably
                  excluded by additional clinical, laboratory, or other diagnostic evaluations.

               9. Patients with a history of cancer in the last 5 years, other than non-melanoma
                  skin cell cancers cured by local resection or carcinoma in situ. Existing
                  non-melanoma skin cell cancers should be removed, the lesion site healed, and
                  residual cancer ruled out before administration of the study drug.

              10. Patients who currently abuse drugs or alcohol.

              11. Patients with evidence (as assessed by the investigator) of active or latent
                  bacterial or viral infections at the time of potential enrollment, including
                  subjects with evidence of human immunodeficiency virus (HIV) detected during
                  screening.

              12. Patients with herpes zoster or cytomegalovirus (CMV) that resolved less than 2
                  months before the informed consent document was signed.

              13. Patients who have received any live vaccines within 3 months of the anticipated
                  first dose of study medication. Subjects may not receive live vaccine
                  concurrently with tofacitinib.

              14. Patients with a history or symptoms suggestive of gastrointestinal perforation or
                  disorders that might increase the risk of GI perforation such as gastric ulcers
                  or diverticulitis.

              15. Patients who take NSAIDs at high dose or on a frequent basis, which in the
                  investigator's opinion might increase the risks of gastrointestinal perforation.

              16. Patients with any serious bacterial infection within the last 3 months, unless
                  treated and resolved with antibiotics, or any chronic bacterial infection (e.g.,
                  chronic pyelonephritis, osteomyelitis, or bronchiectasis).

              17. Patients at risk for tuberculosis (TB). Specifically excluded from this study
                  will be subjects with a history of active TB within the last 3 years, even if it
                  was treated; a history of active TB greater than 3 years ago, unless there is
                  documentation that the prior anti-TB treatment was appropriate in duration and
                  type; current clinical, radiographic, or laboratory evidence of active TB; and
                  latent TB that was not successfully treated (4 weeks).
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Julian Mackay-Wiggan, MD, MS</last_name>
    <role>Principal Investigator</role>
    <affiliation>Columbia University</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Columbia University Medical Center</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10032</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>April 2019</verification_date>
  <study_first_submitted>November 14, 2014</study_first_submitted>
  <study_first_submitted_qc>November 20, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 24, 2014</study_first_posted>
  <results_first_submitted>March 27, 2019</results_first_submitted>
  <results_first_submitted_qc>April 16, 2019</results_first_submitted_qc>
  <results_first_posted type="Actual">May 7, 2019</results_first_posted>
  <last_update_submitted>April 16, 2019</last_update_submitted>
  <last_update_submitted_qc>April 16, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">May 7, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Alopecia Areata</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Alopecia</mesh_term>
    <mesh_term>Alopecia Areata</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Tofacitinib</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>Individual data will be included in the publications, but will not be identifiable.</ipd_description>
    <ipd_time_frame>At the end of the study.</ipd_time_frame>
    <ipd_access_criteria>The data is available in the publication for this study.</ipd_access_criteria>
  </patient_data>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol and Statistical Analysis Plan</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>December 18, 2015</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/97/NCT02299297/Prot_SAP_000.pdf</document_url>
    </provided_document>
  </provided_document_section>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Tofacitinib</title>
          <description>Tofacitinib will be self-administered for 6 months, with the option to extend treatment up to an additional 6 months at the discretion of the principal investigator. Patients will then be followed for 6 months off the drug to assess the incidence and timing of recurrence of disease or documentation of delayed response to treatment.
Tofacitinib: Dosage/Frequency: 5mg - 10mg, oral, twice daily</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="12"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="11"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>Includes all individuals who received treatment.</population>
      <group_list>
        <group group_id="B1">
          <title>Tofacitinib</title>
          <description>Tofacitinib will be self-administered for 6 months, with the option to extend treatment up to an additional 6 months at the discretion of the principal investigator. Patients will then be followed for 6 months off the drug to assess the incidence and timing of recurrence of disease or documentation of delayed response to treatment.
Tofacitinib: Dosage/Frequency: 5mg - 10mg, oral, twice daily</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="12"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>&lt;=18 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Between 18 and 65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="12"/>
                  </measurement_list>
                </category>
                <category>
                  <title>&gt;=65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="8"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>American Indian or Alaska Native</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Native Hawaiian or Other Pacific Islander</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black or African American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="4"/>
                  </measurement_list>
                </category>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="5"/>
                  </measurement_list>
                </category>
                <category>
                  <title>More than one race</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Total Number of Responders</title>
        <description>This is defined as 50% or greater hair re-growth from baseline as assessed by the Severity of ALopecia Tool (SALT) score after up to 24 weeks/6 months to 72 weeks/18 months of treatment. This is a relatively strict definition for defining responders and non-responders and was chosen to minimize the potential for spontaneous remission, in which fewer than 10% are expected to achieve this magnitude of hair regrowth spontaneously.</description>
        <time_frame>Baseline up to between 24 and 72 weeks</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Tofacitinib</title>
            <description>Tofacitinib will be self-administered for 6 months, with the option to extend treatment up to an additional 6 months at the discretion of the principal investigator. Patients will then be followed for 6 months off the drug to assess the incidence and timing of recurrence of disease or documentation of delayed response to treatment.
Tofacitinib: Dosage/Frequency: 5mg - 10mg, oral, twice daily</description>
          </group>
        </group_list>
        <measure>
          <title>Total Number of Responders</title>
          <description>This is defined as 50% or greater hair re-growth from baseline as assessed by the Severity of ALopecia Tool (SALT) score after up to 24 weeks/6 months to 72 weeks/18 months of treatment. This is a relatively strict definition for defining responders and non-responders and was chosen to minimize the potential for spontaneous remission, in which fewer than 10% are expected to achieve this magnitude of hair regrowth spontaneously.</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="12"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Total Number of Responders Maintaining Response During the Post-Treatment Follow Up Period</title>
        <description>To assess the durability of responses, patients who achieve 50% regrowth from baseline during the first 6 to 18 months, will continue to be followed for an additional 6 months post-treatment or until it is determined that relapse has occurred. Durability of response was measured by comparing SALT scores from baseline to 24 weeks after treatment.</description>
        <time_frame>Week 24</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Tofacitinib</title>
            <description>Tofacitinib will be self-administered for 6 months, with the option to extend treatment up to an additional 6 months at the discretion of the principal investigator. Patients will then be followed for 6 months off the drug to assess the incidence and timing of recurrence of disease or documentation of delayed response to treatment.
Tofacitinib: Dosage/Frequency: 5mg - 10mg, oral, twice daily</description>
          </group>
        </group_list>
        <measure>
          <title>Total Number of Responders Maintaining Response During the Post-Treatment Follow Up Period</title>
          <description>To assess the durability of responses, patients who achieve 50% regrowth from baseline during the first 6 to 18 months, will continue to be followed for an additional 6 months post-treatment or until it is determined that relapse has occurred. Durability of response was measured by comparing SALT scores from baseline to 24 weeks after treatment.</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="8"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Total Number of Responders With Change in PHYSICIAN Global Assessment Score</title>
        <description>A physician's assessment of the severity of disease based on a 6-point scale (score of 0 = clear and 5 = very severe). Responders are defined by participants who exhibited regrowth.</description>
        <time_frame>Up to 24 weeks</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Tofacitinib</title>
            <description>Tofacitinib will be self-administered for 6 months, with the option to extend treatment up to an additional 6 months at the discretion of the principal investigator. Patients will then be followed for 6 months off the drug to assess the incidence and timing of recurrence of disease or documentation of delayed response to treatment.
Tofacitinib: Dosage/Frequency: 5mg - 10mg, oral, twice daily</description>
          </group>
        </group_list>
        <measure>
          <title>Total Number of Responders With Change in PHYSICIAN Global Assessment Score</title>
          <description>A physician's assessment of the severity of disease based on a 6-point scale (score of 0 = clear and 5 = very severe). Responders are defined by participants who exhibited regrowth.</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="8"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Regrowth</title>
        <description>Percentage of regrowth was measured by comparing the SALT score at the beginning and end of treatment.</description>
        <time_frame>Baseline up to between 24 and 72 weeks</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Tofacitinib</title>
            <description>Tofacitinib will be self-administered for 6 months, with the option to extend treatment up to an additional 6 months at the discretion of the principal investigator. Patients will then be followed for 6 months off the drug to assess the incidence and timing of recurrence of disease or documentation of delayed response to treatment.
Tofacitinib: Dosage/Frequency: 5mg - 10mg, oral, twice daily</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Regrowth</title>
          <description>Percentage of regrowth was measured by comparing the SALT score at the beginning and end of treatment.</description>
          <units>percentage of regrowth</units>
          <param>Mean</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="12"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="56.8" lower_limit="12.1" upper_limit="100"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Dermatology Life Quality Index (DLQI) Score</title>
        <description>The first dermatology-specific Quality of Life instrument. It is a simple 10-question validated questionnaire used to evaluate patient's quality of life. The DLQI is calculated by summing the score of each question resulting in a maximum of 30 and a minimum of 0. The higher the score, the more quality of life is impaired.</description>
        <time_frame>Up to 24 weeks</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Tofacitinib</title>
            <description>Tofacitinib will be self-administered for 6 months, with the option to extend treatment up to an additional 6 months at the discretion of the principal investigator. Patients will then be followed for 6 months off the drug to assess the incidence and timing of recurrence of disease or documentation of delayed response to treatment.
Tofacitinib: Dosage/Frequency: 5mg - 10mg, oral, twice daily</description>
          </group>
        </group_list>
        <measure>
          <title>Dermatology Life Quality Index (DLQI) Score</title>
          <description>The first dermatology-specific Quality of Life instrument. It is a simple 10-question validated questionnaire used to evaluate patient's quality of life. The DLQI is calculated by summing the score of each question resulting in a maximum of 30 and a minimum of 0. The higher the score, the more quality of life is impaired.</description>
          <units>score on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="12"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6.5" spread="5.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>3 months</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.2" spread="6.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>6 months</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6" spread="6.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Up to 18 months from the start of treatment</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Tofacitinib</title>
          <description>Tofacitinib will be self-administered for 6 months, with the option to extend treatment up to an additional 6 months at the discretion of the principal investigator. Patients will then be followed for 6 months off the drug to assess the incidence and timing of recurrence of disease or documentation of delayed response to treatment.
Tofacitinib: Dosage/Frequency: 5mg - 10mg, oral, twice daily</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="12"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="12" subjects_at_risk="12"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Blood on urinalysis</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="12"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Eye disorders</title>
            <event_list>
              <event>
                <sub_title>Conjunctivitis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="12"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Mild acne</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>Bloating</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>Dizziness</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="12"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Hepatobiliary disorders</title>
            <event_list>
              <event>
                <sub_title>Transaminitis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="12"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Upper respiratory infection</sub_title>
                <counts group_id="E1" events="11" subjects_affected="11" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>Asymptomatic bacteriuria</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="12"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Loose stools</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>Weight gain</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>Constipation</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="12"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Neuropathic pain</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="12"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>increased bowel movement frequency</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>Urinary retention</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="12"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Reproductive system and breast disorders</title>
            <event_list>
              <event>
                <sub_title>Vaginal spotting (post menopause)</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="12"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Hypertensive urgency</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="12"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Grace Ulerio, CCRC</name_or_title>
      <organization>Columbia University Department of Dermatology Clinical Research Unit</organization>
      <phone>212-305-6593</phone>
      <email>gu2102@cumc.columbia.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

